How and when I do allogeneic transplant in CLL
Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibruti...
Gespeichert in:
| Veröffentlicht in: | Blood 2018-07, Vol.132 (1), p.31-39 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 39 |
|---|---|
| container_issue | 1 |
| container_start_page | 31 |
| container_title | Blood |
| container_volume | 132 |
| creator | Gribben, John G. |
| description | Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents. |
| doi_str_mv | 10.1182/blood-2018-01-785998 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6034643</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120321005</els_id><sourcerecordid>2038271005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-4d5d5c74de05b5498c50eca8b5f4173f6d08d6a0ae9812f24b3e015d2e7773973</originalsourceid><addsrcrecordid>eNp9kElPwzAQhS0EgrL8A4Ry5BIYb7FzQUIVm1SJC5wtx56AUWqXOAXx70kp64XTSLO89-Yj5JDCCaWanTZdSr5kQHUJtFRa1rXeIBMq2dgABptkAgBVKWpFd8huzk8AVHAmt8kOq5VkTOoJOblOr4WNvnh9xFjcFD4VtuvSA0YMrhh6G_Ois3EoQiyms9k-2Wptl_Hgs-6R-8uLu-l1Obu9upmez0onKj6UwksvnRIeQTZS1NpJQGd1I1tBFW8rD9pXFizWmrKWiYYjUOkZKqV4rfgeOVvrLpbNHL3DOEbpzKIPc9u_mWSD-TuJ4dE8pBdTAReV4KPA8adAn56XmAczD9lhN_6CaZkNA66ZogByXBXrVdennHtsv20omBVq84HarFAboGaNejw7-h3x--iL7c8POIJ6Cdib7AJGhz706AbjU_jf4R1xGI8V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2038271005</pqid></control><display><type>article</type><title>How and when I do allogeneic transplant in CLL</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gribben, John G.</creator><creatorcontrib>Gribben, John G.</creatorcontrib><description>Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2018-01-785998</identifier><identifier>PMID: 29752258</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Allografts ; Antineoplastic Agents - therapeutic use ; Hematopoietic Stem Cell Transplantation ; How I Treat ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Risk Factors</subject><ispartof>Blood, 2018-07, Vol.132 (1), p.31-39</ispartof><rights>2018 American Society of Hematology</rights><rights>2018 by The American Society of Hematology.</rights><rights>2018 by The American Society of Hematology 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-4d5d5c74de05b5498c50eca8b5f4173f6d08d6a0ae9812f24b3e015d2e7773973</citedby><cites>FETCH-LOGICAL-c463t-4d5d5c74de05b5498c50eca8b5f4173f6d08d6a0ae9812f24b3e015d2e7773973</cites><orcidid>0000-0002-8505-7430</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29752258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gribben, John G.</creatorcontrib><title>How and when I do allogeneic transplant in CLL</title><title>Blood</title><addtitle>Blood</addtitle><description>Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents.</description><subject>Allografts</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>How I Treat</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Risk Factors</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kElPwzAQhS0EgrL8A4Ry5BIYb7FzQUIVm1SJC5wtx56AUWqXOAXx70kp64XTSLO89-Yj5JDCCaWanTZdSr5kQHUJtFRa1rXeIBMq2dgABptkAgBVKWpFd8huzk8AVHAmt8kOq5VkTOoJOblOr4WNvnh9xFjcFD4VtuvSA0YMrhh6G_Ois3EoQiyms9k-2Wptl_Hgs-6R-8uLu-l1Obu9upmez0onKj6UwksvnRIeQTZS1NpJQGd1I1tBFW8rD9pXFizWmrKWiYYjUOkZKqV4rfgeOVvrLpbNHL3DOEbpzKIPc9u_mWSD-TuJ4dE8pBdTAReV4KPA8adAn56XmAczD9lhN_6CaZkNA66ZogByXBXrVdennHtsv20omBVq84HarFAboGaNejw7-h3x--iL7c8POIJ6Cdib7AJGhz706AbjU_jf4R1xGI8V</recordid><startdate>20180705</startdate><enddate>20180705</enddate><creator>Gribben, John G.</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8505-7430</orcidid></search><sort><creationdate>20180705</creationdate><title>How and when I do allogeneic transplant in CLL</title><author>Gribben, John G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-4d5d5c74de05b5498c50eca8b5f4173f6d08d6a0ae9812f24b3e015d2e7773973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Allografts</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>How I Treat</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gribben, John G.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gribben, John G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How and when I do allogeneic transplant in CLL</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2018-07-05</date><risdate>2018</risdate><volume>132</volume><issue>1</issue><spage>31</spage><epage>39</epage><pages>31-39</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29752258</pmid><doi>10.1182/blood-2018-01-785998</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8505-7430</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2018-07, Vol.132 (1), p.31-39 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6034643 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Allografts Antineoplastic Agents - therapeutic use Hematopoietic Stem Cell Transplantation How I Treat Humans Leukemia, Lymphocytic, Chronic, B-Cell - therapy Risk Factors |
| title | How and when I do allogeneic transplant in CLL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A43%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20and%20when%20I%20do%20allogeneic%20transplant%20in%20CLL&rft.jtitle=Blood&rft.au=Gribben,%20John%20G.&rft.date=2018-07-05&rft.volume=132&rft.issue=1&rft.spage=31&rft.epage=39&rft.pages=31-39&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2018-01-785998&rft_dat=%3Cproquest_pubme%3E2038271005%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2038271005&rft_id=info:pmid/29752258&rft_els_id=S0006497120321005&rfr_iscdi=true |